• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Predictors for upstaging of ductal carcinoma (DCIS) to invasive carcinoma in non-mass-type DCIS.非肿块型导管原位癌(DCIS)进展为浸润性癌的分期上调预测因素。
Mol Clin Oncol. 2020 Jul;13(1):67-72. doi: 10.3892/mco.2020.2036. Epub 2020 Apr 27.
2
An Updated Nomogram for Predicting Invasiveness in Preoperative Ductal Carcinoma In Situ of the Breast.术前乳腺导管原位癌侵袭性的列线图预测更新。
Yonsei Med J. 2019 Nov;60(11):1028-1035. doi: 10.3349/ymj.2019.60.11.1028.
3
Symptomatic ductal carcinoma in situ (DCIS): Upstaging risk and predictors.有症状的导管原位癌(DCIS):升级风险和预测因素。
Clin Imaging. 2021 May;73:101-107. doi: 10.1016/j.clinimag.2020.11.050. Epub 2020 Dec 3.
4
Is there a role of sentinel lymph node biopsy in ductal carcinoma in situ?: analysis of 587 cases.前哨淋巴结活检在导管原位癌中是否有作用?:587例病例分析
Breast Cancer Res Treat. 2006 Aug;98(3):311-4. doi: 10.1007/s10549-006-9167-2. Epub 2006 Mar 22.
5
Preoperatively diagnosed ductal cancers in situ of the breast presenting as even small masses are of high risk for the invasive cancer foci in postoperative specimen.术前诊断为原位导管癌的乳腺,即使表现为小肿块,术后标本中出现浸润性癌灶的风险也很高。
World J Surg Oncol. 2015 Jul 16;13:218. doi: 10.1186/s12957-015-0641-3.
6
A model to predict upstaging to invasive carcinoma in patients preoperatively diagnosed with ductal carcinoma in situ of the breast.一种用于预测术前诊断为乳腺导管原位癌患者进展为浸润性癌的模型。
J Surg Oncol. 2015 Oct;112(5):476-80. doi: 10.1002/jso.24037. Epub 2015 Sep 8.
7
Evaluating the Risk of Upstaging HER2-Positive DCIS to Invasive Breast Cancer.评估 HER2 阳性 DCIS 升级为浸润性乳腺癌的风险。
Ann Surg Oncol. 2017 Oct;24(10):2999-3003. doi: 10.1245/s10434-017-5941-0. Epub 2017 Aug 1.
8
Predictors of residual invasive disease after core needle biopsy diagnosis of ductal carcinoma in situ.导管原位癌粗针活检诊断后残留浸润性疾病的预测因素。
Breast J. 2007 May-Jun;13(3):251-7. doi: 10.1111/j.1524-4741.2007.00418.x.
9
Preoperatively diagnosed ductal carcinoma in situ: risk prediction of invasion and effects on axillary management.术前诊断的导管原位癌:浸润风险预测及对腋窝处理的影响
Breast Cancer. 2016 Sep;23(5):761-70. doi: 10.1007/s12282-015-0636-5. Epub 2015 Sep 1.
10
Factors associated with upstaging in patients preoperatively diagnosed with ductal carcinoma by core needle biopsy.术前经粗针穿刺活检诊断为导管癌的患者中与分期上调相关的因素。
Cancer Biol Med. 2019 May;16(2):312-318. doi: 10.20892/j.issn.2095-3941.2018.0159.

引用本文的文献

1
Prediction of upstaging in DCIS: the dominant role of pathological over imaging risk factors.导管原位癌(DCIS)分期升级的预测:病理因素相较于影像学风险因素的主导作用
Breast Cancer Res Treat. 2025 Oct;213(3):325-334. doi: 10.1007/s10549-025-07768-6. Epub 2025 Aug 1.
2
Systematic assessment of HER2 status in ductal carcinoma in situ of the breast: a perspective on the potential clinical relevance.系统评估乳腺导管原位癌的 HER2 状态:潜在临床相关性的视角。
Breast Cancer Res. 2024 Aug 27;26(1):125. doi: 10.1186/s13058-024-01875-w.
3
Magnetic resonance imaging diagnosis of non-mass enhancement of the breast.磁共振成像诊断非肿块性乳腺增强。
J Med Ultrason (2001). 2023 Jul;50(3):361-366. doi: 10.1007/s10396-023-01290-2. Epub 2023 Feb 18.
4
Subtype-Specific Tumour Immune Microenvironment in Risk of Recurrence of Ductal Carcinoma In Situ: Prognostic Value of HER2.导管原位癌复发风险中的亚型特异性肿瘤免疫微环境:HER2的预后价值
Biomedicines. 2022 May 3;10(5):1061. doi: 10.3390/biomedicines10051061.
5
Breast cancer in Trinidad and Tobago: Etiopathogenesis, histopathology and receptor study.特立尼达和多巴哥的乳腺癌:病因发病机制、组织病理学及受体研究
J Family Med Prim Care. 2021 Dec;10(12):4438-4445. doi: 10.4103/jfmpc.jfmpc_627_21. Epub 2021 Dec 27.

本文引用的文献

1
Evaluating the Risk of Upstaging HER2-Positive DCIS to Invasive Breast Cancer.评估 HER2 阳性 DCIS 升级为浸润性乳腺癌的风险。
Ann Surg Oncol. 2017 Oct;24(10):2999-3003. doi: 10.1245/s10434-017-5941-0. Epub 2017 Aug 1.
2
The Relationships between HER2 Overexpression and DCIS Characteristics.人表皮生长因子受体2(HER2)过表达与导管原位癌特征之间的关系
Breast J. 2017 May;23(3):307-314. doi: 10.1111/tbj.12735. Epub 2016 Dec 10.
3
Preoperatively diagnosed ductal carcinoma in situ: risk prediction of invasion and effects on axillary management.术前诊断的导管原位癌:浸润风险预测及对腋窝处理的影响
Breast Cancer. 2016 Sep;23(5):761-70. doi: 10.1007/s12282-015-0636-5. Epub 2015 Sep 1.
4
Large palpable ductal carcinoma in situ is Her-2 positive with high nuclear grade.可触及的大导管原位癌为Her-2阳性,核分级高。
Int J Clin Exp Pathol. 2015 Apr 1;8(4):3963-70. eCollection 2015.
5
Investigation of the freely available easy-to-use software 'EZR' for medical statistics.医学统计学中免费易用软件 EZR 的调查研究。
Bone Marrow Transplant. 2013 Mar;48(3):452-8. doi: 10.1038/bmt.2012.244. Epub 2012 Dec 3.
6
Predictors of invasive breast cancer and lymph node involvement in ductal carcinoma in situ initially diagnosed by vacuum-assisted breast biopsy: experience of 733 cases.真空辅助乳腺活检诊断的导管原位癌中浸润性乳腺癌和淋巴结受累的预测因素:733 例经验。
Breast. 2012 Oct;21(5):635-40. doi: 10.1016/j.breast.2012.06.009. Epub 2012 Jul 12.
7
Ductal carcinoma in situ at core-needle biopsy: meta-analysis of underestimation and predictors of invasive breast cancer.乳腺导管原位癌的核心针活检:低估的荟萃分析和浸润性乳腺癌的预测因素。
Radiology. 2011 Jul;260(1):119-28. doi: 10.1148/radiol.11102368. Epub 2011 Apr 14.
8
Sonographic lesion size of ductal carcinoma in situ as a preoperative predictor for the presence of an invasive focus.导管原位癌的超声病变大小作为术前预测浸润性病灶存在的指标。
J Surg Oncol. 2008 Jul 1;98(1):15-20. doi: 10.1002/jso.21077.
9
Predictors of residual invasive disease after core needle biopsy diagnosis of ductal carcinoma in situ.导管原位癌粗针活检诊断后残留浸润性疾病的预测因素。
Breast J. 2007 May-Jun;13(3):251-7. doi: 10.1111/j.1524-4741.2007.00418.x.
10
Predictors of invasive disease in breast cancer when core biopsy demonstrates DCIS only.当粗针活检仅显示导管原位癌时,乳腺癌侵袭性疾病的预测因素。
J Surg Oncol. 2006 Jun 1;93(7):559-63. doi: 10.1002/jso.20445.

非肿块型导管原位癌(DCIS)进展为浸润性癌的分期上调预测因素。

Predictors for upstaging of ductal carcinoma (DCIS) to invasive carcinoma in non-mass-type DCIS.

作者信息

Oda Goshi, Nakagawa Tsuyoshi, Ogawa Ayumi, Kumaki Yuichi, Hosoya Tokuko, Sugimoto Hitoshi, Ishiba Toshiyuki, Mio Mori, Fujioka Tomoyuki, Kubota Kazunori, Onishi Iichiroh, Uetake Hiroyuki

机构信息

Department of Surgical Specialties, Tokyo Medical and Dental University, Graduate School of Medicine and Dentistry, Bunkyo-ku, Tokyo 113-8519, Japan.

Department of Radiology, Tokyo Medical and Dental University, Graduate School of Medicine and Dentistry, Bunkyo-ku, Tokyo 113-8519, Japan.

出版信息

Mol Clin Oncol. 2020 Jul;13(1):67-72. doi: 10.3892/mco.2020.2036. Epub 2020 Apr 27.

DOI:10.3892/mco.2020.2036
PMID:32454975
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7243301/
Abstract

Preoperatively diagnosed ductal carcinoma (DCIS) is sometimes upstaged to invasive cancer by postoperative pathological examination. Various preoperative factors associated with upstaging to invasive cancer have been reported; however, this subject remains to be clarified. DCIS takes various forms on imaging, but many cases show non-mass-type lesions. In non-mass-type DCIS, recognizing the presence of invasion is difficult. To investigate predictors associated with upstaging to invasive cancer more precisely, we examined only non-mass-type DCIS. The present study retrospectively analyzed 101 patients diagnosed with non-mass-type DCIS preoperatively on breast biopsy at our institution between 2007 and 2017. Data were analyzed using Fisher's exact probability test and two-sample t-tests. Multivariate analysis was performed using logistic regression. The results showed that 27 patients (27%) were finally diagnosed with invasive cancer. Univariate analysis revealed abnormal result of palpation on breast examination (P=0.05), comedo necrosis (P=0.05), and HER2 status (P=0.02) as significant predictors. Multivariate analysis revealed an abnormal result of palpation as an independent predictor of invasive cancer underestimation (odds ratio 4.76; confidence interval 1.44-15.7; P=0.01). In conclusion, preoperatively diagnosed non-mass-type DCIS represented an underestimation in approximately 27% of cases. In particular, the presence of a clinically abnormal palpation increases the chance of upstaging to invasive cancer.

摘要

术前诊断为导管原位癌(DCIS)的病例,术后病理检查有时会被升级为浸润性癌。已有多种与升级为浸润性癌相关的术前因素被报道;然而,这一问题仍有待阐明。DCIS在影像学上有多种表现形式,但许多病例表现为非肿块型病变。在非肿块型DCIS中,识别浸润的存在较为困难。为了更精确地研究与升级为浸润性癌相关的预测因素,我们仅研究了非肿块型DCIS。本研究回顾性分析了2007年至2017年间在我院经乳腺活检术前诊断为非肿块型DCIS的101例患者。数据采用Fisher精确概率检验和两样本t检验进行分析。使用逻辑回归进行多变量分析。结果显示,27例患者(27%)最终被诊断为浸润性癌。单变量分析显示,乳腺检查触诊结果异常(P=0.05)、粉刺样坏死(P=0.05)和HER2状态(P=0.02)是显著的预测因素。多变量分析显示,触诊结果异常是浸润性癌低估的独立预测因素(比值比4.76;置信区间1.44-15.7;P=0.01)。总之,术前诊断的非肿块型DCIS在约27%的病例中存在低估情况。特别是,临床触诊异常增加了升级为浸润性癌的可能性。